Influence of Asparaginase on a Combination Chemotherapy Protocol for Canine Multicentric Lymphoma

2005 ◽  
Vol 41 (4) ◽  
pp. 221-226 ◽  
Author(s):  
Antonella Borgatti Jeffreys ◽  
Deborah W. Knapp ◽  
William W. Carlton ◽  
Rosanne M. Thomas ◽  
Patty L. Bonney ◽  
...  
Keyword(s):  
Clinical Response ◽  
Combination Chemotherapy ◽  
Clinical Remission ◽  
Single Agent ◽  
Induction Phase ◽  
Canine Lymphoma ◽  
Free Interval ◽  
Chemotherapy Protocol ◽  
Multicentric Lymphoma ◽  
Single Agent Chemotherapy

Combination chemotherapy is superior to single-agent chemotherapy for treating canine lymphoma, but the effect of each drug on efficacy remains unknown. By comparing 34 dogs treated with a modified cyclophosphamide, vincristine, prednisone (COP) chemotherapy protocol and 42 dogs given asparaginase in the induction phase of the same protocol, the effect of asparaginase on the chemotherapeutic protocol was determined. Both groups were compared based on clinical response at 2 weeks and 6 weeks, and on the progression-free interval. Asparaginase did not significantly increase the likelihood of a clinical remission or prolong the initial progression-free interval in the dogs studied.

scholarly journals Primary Nongestational Choriocarcinoma of the Ovary

2014 ◽  
Vol 4 (1) ◽  
pp. 56-59
Author(s):  
AMM Shariful Alam ◽  
Syeda Nurjahan Bhuiyan ◽  
Md Rashid Un Nabi
Keyword(s):  
Germ Cell ◽  
Combination Chemotherapy ◽  
Single Agent ◽  
Ovarian Pregnancy ◽  
Cell Neoplasm ◽  
Aggressive Tumor ◽  
Single Agent Chemotherapy ◽  
Disease Free ◽  
Worse Prognosis ◽  
Unmarried Girl

Pure primary ovarian choriocarcinoma is an extremely rare and aggressive tumor. It can be of gestational or nongestational in origin. The gestational type can arise from an ovarian pregnancy or can be of metastatic origin from uterine choriocarcinoma. The nongestational type is a very rare germ cell neoplasm. It is important to distinguish between two types of choriocarcinomas as nongestational origin is highly malignant and has worse prognosis than gestational type. But it is very difficult to differentiate by routine histological examination. Nongestational choriocarcinoma has been found to be resistant to single agent chemotherapy. It occurs usually around 13 years of age and is mainly confined to females under 20. Here we report a case of primary pure nongestational choriocarcinoma of the ovary in an unmarried girl of 14 years, diagnosed in 2001 and treated successfully with surgery and combination chemotherapy and remained disease-free till last reporting in September 2013. DOI: http://dx.doi.org/10.3329/jemc.v4i1.18070 J Enam Med Col 2014; 4(1): 56-59

scholarly journals Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH

2017 ◽  
Vol 1 (6) ◽  
pp. 352-356 ◽  
Author(s):  
Alexandra Kolenová ◽  
Raphaela Schwentner ◽  
Gunhild Jug ◽  
Ingrid Simonitsch-Klupp ◽  
Christoph Kornauth ◽  
...  
Keyword(s):  
Clinical Response ◽  
Clinical Remission ◽  
Mapk Pathway ◽  
Single Agent ◽  
Braf V600e ◽  
Longitudinal Assessment ◽  
Key Points ◽  
Life Threatening ◽  
Targeted Inhibition

Key Points Single-agent vemurafenib leads to a rapid and sustained clinical response in severe multisystem LCH but does not eradicate the disease. Longitudinal assessment of BRAF V600E during treatment shows that clinical remission can occur despite significant amounts of mutated BRAF.

scholarly journals A case of methotrexate resistant gestational trophoblastic neoplasia

2018 ◽  
Vol 7 (12) ◽  
pp. 5178
Author(s):  
Sanjay Singh ◽  
Akhileshwar Singh ◽  
Shakti Vardhan
Keyword(s):  
High Risk ◽  
Combination Chemotherapy ◽  
Single Agent ◽  
Gestational Trophoblastic Disease ◽  
Gestational Trophoblastic Neoplasia ◽  
Trophoblastic Disease ◽  
Peripheral Hospital ◽  
Invasive Mole ◽  
Single Agent Chemotherapy

Gestational trophoblastic neoplasia (GTN) is a subset of gestational trophoblastic disease (GTD) which has a propensity to invade locally and metastasize. Patients with low risk GTN generally respond well to single agent chemotherapy (methotrexate (MTX) or actinomycin-D (ACT-D). However, high risk cases may develop resistance or may not respond to this first-line chemotherapy and are unlikely to be cured with single-agent therapy. Therefore, combination chemotherapy is used for treatment of these cases. Here we present a 25 years old P2 L2 A1 lady, who was initially treated at a peripheral hospital with multiple doses of Injection methotrexate with a working diagnosis of persistent trophoblastic disease. She didn’t respond to this treatment and reported to our centre for further management. On evaluation she was found to be a case of high risk GTN (invasive mole) (I:8) for which she was put on combination chemotherapy in the form of Etoposide-Methotrexate-Actinomycin-Cyclophosphamide-Oncovin (EMA-CO) regime. She responded to this treatment and is presently asymptomatic and is under regular follow up.

scholarly journals The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma

Cancer ◽  
1979 ◽  
Vol 44 (2) ◽  
pp. 406-413 ◽  
Author(s):  
Stanley Lowenbraun ◽  
Al Bartolucci ◽  
Richard V. Smalley ◽  
Michael Lynn, Ba, Stephen Krauss ◽  
John R. Durant ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Combination Chemotherapy ◽  
Small Cell Lung Carcinoma ◽  
Single Agent ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Single Agent Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document